February 16, 2018
1 min read

NEXT: Biodegradable DES remains noninferior to durable stent at 5 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Masahiro Natsuaki, MD
Masahiro Natsuaki

A biodegradable-polymer biolimus-eluting stent was noninferior to a durable-polymer everolimus eluting stent at 5 years, according new data from the NEXT trial.

The results are consistent with 1-year and 2-year data, researchers reported.

In the large, prospective, multicenter, randomized, open-label trial, Masahiro Natsuaki, MD, from the department of cardiovascular medicine, Saga University, Japan, and colleagues randomly assigned 3,235 patients (mean age, 69 years; 46% with diabetes; 51% with prior PCI) to receive the biolimus-eluting stent (Nobori, Terumo; n = 1,617) or an everolimus-eluting stent (Xience, Abbott Vascular; n = 1,618).

At 5 years, 93.8% of patients were available for follow-up.

The primary safety endpoint of death or MI occurred in 15.1% of patients assigned the biodegradable-polymer stent vs. 16.5% of those assigned the durable-polymer stent at 5 years (HR = 0.91; 95% CI, 0.75-1.11; P for noninferiority < .0001), according to the researchers.

The primary efficacy endpoint of target lesion revascularization occurred in 9.8% of those in the biodegradable group and 9.3% of those in the durable group at 5 years (HR = 1.04; 95% CI, 0.8-1.34; P for noninferiority = .01), they wrote.

Cumulative incidences of death/MI, TLR and definite stent thrombosis between 1 year and 5 years were not different between the groups.

The results were consistent across subgroups, including diabetes status, insulin use, age, hemodialysis and multivessel vs. single-vessel PCI, Natsuaki and colleagues wrote.

“Both the biodegradable polymer and the durable polymer might have achieved the parallel improvements using more biocompatible polymers than those used in first-generation DES,” the researchers wrote. – by Erik Swain

Disclosure: The study was funded by Terumo. Natsuaki reports he received lecture fees from Abbott Vascular Japan and Terumo Japan. Please see the study for a list of the other authors’ relevant financial disclosures.